Loading clinical trials...

Nebulized Heparin for COVID19-associated Acute Respiratory Failure | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Utilization of Nebulized Heparin for Patients Receiving Mechanical Ventilation for COVID19-associated Acute Respiratory Failure

NCT04842292•Brittany Bissell

View on ClinicalTrials.gov

Summary

The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients admitted with confirmed COVID-19 receiving mechanical ventilation for ARDS (paO2/FiO2 ratio =300) within 48 hours

Exclusion Criteria

•Allergy to heparin
•Any history of heparin-induced thrombocytopenia
•High risk of bleeding (platelet count \< 50,000/µL or international normalized ratio \> 1.5)
•Patients with known bleeding disorders (i.e. hemophilia or von Willebrand Disease)
•Active bleeding
•Pulmonary bleeding during this hospital admission (Pulmonary bleeding is frank bleeding in the lungs, trachea or bronchi with repeated hemoptysis, or requiring repeated suctioning, and temporally associated with acute deterioration in respiratory status)
•Neurosurgical procedures during this hospital admission or such procedures are planned
•Epidural catheter in place
•Any history of intracranial, spinal or epidural hemorrhage
•Tracheostomy in place
+9 more criteria

Locations (1)

UK Healthcare

Lexington, Kentucky, United States

Key Dates

Start Date

May 20, 2021

Primary Completion Date

September 4, 2021

Completion Date

September 4, 2021

Last Updated

October 18, 2022

Enrollment

ACTUAL participants

Conditions

Covid19

Interventions

Heparin

DRUG

Placebo

DRUG

The Effect of the Covid-19 Pandemic Among Operated Patients

NCT04525716

Covid19Surgery

View study

RECRUITINGPHASE3

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796

Critical IllnessVitamin D Deficiency+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Inclusion Criteria

Exclusion Criteria

The Effect of the Covid-19 Pandemic Among Operated Patients

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

Covid-19 and Influenza Oral Vaccine Study

Conversations You Want About Corona Virus Disease (COVID-19)

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy